Impact of clinical pharmacist participation in stroke team activations on tissue plasminogen activator door‐to‐needle time

Abstract

AbstractINTRODUCTIONCurrent stroke guidelines recommend that treatment with tissue plasminogen activator (tPA) should be initiated as quickly as possible in eligible patients to provide maximum therapeutic benefit. Pharmacists possess multiple skills including knowledge of dosing, reconstitution, and improved access to medication that may positively impact door‐to‐needle (DTN) times for patients with acute ischemic stroke.OBJECTIVEThe objective was to evaluate the impact of a clinical pharmacist on time to tPA administration in patients with acute ischemic stroke.METHODSThis was a retrospective, single‐center cohort study at a community teaching hospital and certified primary stroke center from January 1, 2014 to December 31, 2018. The primary outcome of this study was to compare the average DTN time with a pharmacist present at a stroke team activation vs no pharmacist present. Secondary outcomes included the proportion of patients in each group meeting a DTN time of less than 60 minutes and the proportion of patients in each group meeting a DTN time of less than 45 minutes. Statistical analysis utilized included Wilson's t‐test to compare average DTN time and the odds ratio to determine a DTN time <60 or 45 minutes between the pharmacist and non‐pharmacist groups.RESULTSPharmacist involvement was associated with a reduction in the average DTN time: 66 minutes vs 78 minutes (P = .038). The DTN time of less than 60 minutes was met in 60% of cases with a pharmacist present compared with 35% without a pharmacist (P = .005). The DTN time of less than 45 minutes was met in 18% of cases with a pharmacist present vs 20% without a pharmacist (P = .71).CONCLUSIONPharmacist participation in stroke teams in the emergency department may reduce DTN times and increase the likelihood of a patient receiving tPA in less than 60 minutes.